Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group-Reference-Cited by-同舟云学术

Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group

Published:2017-08-14 Issue:12 Volume:31 Page:2833-2837
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Hoechstetter M A,Busch R,Eichhorst B,Bühler A,Winkler D,Eckart M J,Vehling-Kaiser U,Schimke H,Jäger U,Hurtz H J,Hopfinger G,Hartmann F,Fuss H,Abenhardt W,Blau I,Freier W,Müller L,Goebeler M,Wendtner C M,Bahlo J,Fischer K,Bentz M,Emmerich B,Döhner H,Hallek M,Stilgenbauer S

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

https://www.nature.com/articles/leu2017246.pdf

Reference15 articles.

1. Siegel RL, Miller KD, Jemal A . Cancer statistics, 2017. CA Cancer J Clin 2017; 67: 7–30.

2. Dighiero G, Maloum K, Desablens B, Cazin B, Navarro M, Leblay R et al. Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. N Engl J Med 1998; 338: 1506–1514.

3. Montserrat E, Sanchez-Bisono J, Vinolas N, Rozman C . Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance. Br J Haematol 1986; 62: 567–575.

4. Rozman C, Montserrat E, Rodríguez-Fernández JM, Ayats R, Vallespí T, Parody R et al. Bone marrow histologic pattern—the best single prognostic parameter in chronic lymphocytic leukemia: a multivariate survival analysis of 329 cases. Blood 1984; 64: 642–648.

5. Langenmayer I, Nerl C, Knauf W, Adorf D, Hallek M, Dietzfelbinger H et al. Interferon alpha 2b in the treatment of early stage CLL with risk for progression. Results of a randomized multicenter study. Br J Haematol 1996; 94: 362–369.

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk scores predicting disease progression in early‐stage CLL: Comparative analysis and usefulness of IGHV subset #2 to improve their accuracy;Cancer;2024-09-12

2. Chronic lymphocytic leukaemia;The Lancet;2024-08

3. Realizing precision medicine in chronic lymphocytic leukemia: Remaining challenges and potential opportunities;HemaSphere;2024-07

4. ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia—2024 update;Leukemia;2024-05-16

5. Improved Survival of Patients With Chronic Lymphocytic Leukemia Between 1998-2022, Including the Era of Target Therapies With BCL2 and BTK Inhibitors;Anticancer Research;2024-04-27